Exclusive: GT Biopharma promotes a recurrent blood cancer therapy study to cohort 2 after promising early safety results – GT Biopharma (Nasdaq: GTBP)

GT Biopharma, Inc. GTBP announced on Monday that it successfully completed the dosage in cohort 1 and started dosing in cohort 2 of his phase 1 dose of escalation study for GTB-3650. The therapy is a trike-therapeutic targeting of the second generation, refunded or refractory CD33-to expression hematological malignancies.

GT Biopharma specializes in immuno-oncology therapies with the help of its own Trike NK Cell Intager platform and has an exclusive global license at the University of Minnesota for development and commercialization.

No problems with safety or tolerability were observed in cohort 1, which made progression to the next cohort possible, the company said.

Early biomarker analysis of cohort 1 patients indicates increased immunological activity, which indicates activation and expansion of natural murderer (NK) cells.

The study, which can include up to 14 patients in seven cohorts, includes two weeks of dosage blocks for a period of four months and will evaluate safety, pharmacokinetics, pharmacodynamics, NK cell expansion and clinical activity.

The company said that the detailed results will release in 2025.

In January, the company had initiated the dosage of the patient with GTB-3650 in the phase 1 study to evaluate the potential in patients with hematological malignancy.

Price promotion: GTBP -shares traded higher with 0.90% to $ 2.26 premarket at the last check on Monday.

Read next:

Photo by Aunt Spray via Shutterstock